Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria.
Department of Medical Statistics, Medical University of Vienna, Vienna, Austria.
J Thorac Cardiovasc Surg. 2018 May;155(5):2193-2206.e3. doi: 10.1016/j.jtcvs.2017.10.144. Epub 2017 Dec 7.
The value of intraoperative extracorporeal membrane oxygenation (ECMO) in lung transplantation remains controversial. In our department, ECMO has been used routinely for intraoperatively unstable patients for more than 15 years. Recently, we have extended its indication to a preemptive application in almost all cases. In addition, we prolong ECMO into the early postoperative period whenever graft function does not meet certain quality criteria or in patients with primary pulmonary hypertension. The objective of this study was to review the results of this strategy.
All standard bilateral lung transplantations performed between January 2010 and June 2016 were included in this single-center, retrospective analysis. Patients were divided into 3 groups: group I-no ECMO (n = 116), group II-intraoperative ECMO (n = 343), and group III-intraoperative and prolonged postoperative ECMO (n = 123). The impact of different ECMO strategies on primary graft function, short-term outcomes, and patient survival were analyzed.
The use of intraoperative ECMO was associated with improved 1-, 3-, and 5-year survival compared with non-ECMO patients (91% vs 82%, 85% vs 76%, and 80% vs 74%; log-rank P = .041). This effect was still evident after propensity score matching of both cohorts. Despite the high number of complex patients in group III, outcome was excellent with higher survival rates than in the non-ECMO group at all time points.
Intraoperative ECMO results in superior survival when compared with transplantation without any extracorporeal support. The concept of prophylactic postoperative ECMO prolongation is associated with excellent outcomes in recipients with pulmonary hypertension and in patients with questionable graft function at the end of implantation.
体外膜肺氧合(ECMO)在肺移植中的价值仍存在争议。在我们科室,ECMO 已常规用于 15 年以上术中不稳定的患者。最近,我们将其适应证扩展到几乎所有病例的预防性应用。此外,只要移植物功能不符合某些质量标准或原发性肺动脉高压患者,我们就会将 ECMO 延长到术后早期。本研究的目的是回顾该策略的结果。
本单中心回顾性分析纳入了 2010 年 1 月至 2016 年 6 月期间进行的所有标准双侧肺移植。患者分为 3 组:组 I-无 ECMO(n=116),组 II-术中 ECMO(n=343),组 III-术中及术后延长 ECMO(n=123)。分析了不同 ECMO 策略对原发性移植物功能、短期结果和患者生存率的影响。
与非 ECMO 患者相比,术中 ECMO 的使用与改善的 1 年、3 年和 5 年生存率相关(91%比 82%,85%比 76%和 80%比 74%;log-rank P=0.041)。在对两组患者进行倾向评分匹配后,这种效果仍然明显。尽管组 III 中有大量复杂患者,但在所有时间点,与非 ECMO 组相比,结果均非常出色,生存率更高。
与没有任何体外支持的移植相比,术中 ECMO 可提高生存率。预防性术后 ECMO 延长的概念与肺动脉高压患者和植入结束时移植物功能可疑的患者的出色结果相关。